2014
DOI: 10.18632/aging.100690
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer's disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

7
129
0
5

Year Published

2017
2017
2017
2017

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 150 publications
(141 citation statements)
references
References 33 publications
(41 reference statements)
7
129
0
5
Order By: Relevance
“…Our previous work using a similar herbal formula called GAPT can markedly enhance learning and memory of AD rat models induced by Aβ injection or transgenic mice of APPV717I and APPs we/PS1dE9 [13], and also showed a significant improvement on cognitive function in patients with amnestic mild cognitive impairment, an early stage of AD (n = 101), consistently across different cognitive cales in a small sample of clinical trial [14]. The good effects of multiple combined therapy in treating MCI (mild cognitive impairment) and SCI (subjective cognitive impairment) and AD, was published by Dale E. Bredesen et al [15] [16]. A therapeutic approach characterized by programmatic, personalization, as well as dubbed metabolic enhancement for neurodegeneration (MEND protocol) was used.…”
Section: Discussionmentioning
confidence: 87%
“…Our previous work using a similar herbal formula called GAPT can markedly enhance learning and memory of AD rat models induced by Aβ injection or transgenic mice of APPV717I and APPs we/PS1dE9 [13], and also showed a significant improvement on cognitive function in patients with amnestic mild cognitive impairment, an early stage of AD (n = 101), consistently across different cognitive cales in a small sample of clinical trial [14]. The good effects of multiple combined therapy in treating MCI (mild cognitive impairment) and SCI (subjective cognitive impairment) and AD, was published by Dale E. Bredesen et al [15] [16]. A therapeutic approach characterized by programmatic, personalization, as well as dubbed metabolic enhancement for neurodegeneration (MEND protocol) was used.…”
Section: Discussionmentioning
confidence: 87%
“…There is now a growing awareness that comprehensive management of ill health requires multiple approaches including management of lifestyle factors. An example of the preliminary data showing signs of success using multiple approaches is the reversal of the cognitive decline in people with Alzheimer's and cognitive impairment, which includes an individualized, iterative, multi-pronged program including optimising biomarkers, nutritional supplements, fasting, exercise, brain stimulation, stress reduction and sleep optimization [81,82].…”
Section: Discussionmentioning
confidence: 99%
“…A therapeutic strategy for mild cognitive impairment and early AD has been devised, which attempts to improve simultaneously multiple nutritional, endocrinological and mitochondrial dysfunctions. The MEND protocol (Metabolic Enhancement for NeuroDegeneration) has achieved some success in subjects with early dementia [26]. One potential refinement of such a protocol would be to examine how the MEND approach alters gene and miRNA expression in peripheral cells, or perhaps neural membrane exosomes [27].…”
Section: Discussionmentioning
confidence: 99%
“…By using this approach we were able to identify a core set of regulated mRNA's in AD that may have their expression increased by loss of specific miRNA's. Whether therapeutic strategies directed at multiple molecular systems, such as the MEND protocol that appears to improve cognitive function [26], alter expressions of miRNA's or mRNA's remains to be tested.…”
Section: Discussionmentioning
confidence: 99%